Non-viral, large-scale delivery of gene editing tools for T cell manufacturing
Stefanie Müthel, Andrea Toell
18 September 2025
Register
Exploring scalable, data-driven AAV manufacturing to achieve high yield and quality across serotypes
Xiaojun Liu, Chris Brown, Yeonji Kim
Learn how to design a simplified, cost-effective LVV manufacturing workflow
Nicole Votaw, Thomas Robert
Exploring key regulatory considerations to ensure patient safety in the gene therapy space
L Shaw, C Le Bec, M Orio et al
Exploring the advantages of ready-to-use lipid-based gene delivery for gene-modified cell therapy
Chesney Michels, Claire Guéguen
Making robust choices: evaluating materials in your AAV process
Michael Bodo, Birgit Rogell
Optimizing plasmid DNA purification: strategies for reliable and expandable processes
Christy Franco, Jasmina Puc
Transforming viral vector manufacturing with next-generation CGMP plasmids platform
John Bowen, Brian Tomkowicz
Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing
Rob Noel, Geddy Hamblen, Christel Fenge
Efficient AAV purification: resin reuse and scalable polish method
Nicolas Laroudie, Duncan Dulac
Industrialization of AAV manufacturing with Xcite® transient and stable production platforms
Suparna Sanyal, Peng Wang
AAV capsid analysis and quantification with chromatography and ultracentrifugation-based techniques
Andreja Livk, Sebastijan Peljhan
Modernizing viral clearance study strategy: regulatory updates and industry best practices
Audrey Chang, Kathleen Kenney